Clinical Roundup City of Hope study suggests adding the drug berzosertib to standard treatment for metastatic bladder cancer does not benefit patients September 03, 2021Vol.47 No.32
Clinical Roundup Yale Cancer Center report highlights NSCLC treatment advances September 03, 2021Vol.47 No.32
Drugs & Targets FDA requires monitoring of long-term clinical outcomes for robotic surgery in breast cancer September 03, 2021Vol.47 No.32
Drugs & Targets Tibsovo receives FDA approval for advanced or metastatic cholangiocarcinoma September 03, 2021Vol.47 No.32
Drugs & Targets Opdivo receives FDA approval for adjuvant treatment of urothelial carcinoma September 03, 2021Vol.47 No.32
Drugs & Targets Jemperli receives FDA accelerated approval for dMMR advanced solid tumors September 03, 2021Vol.47 No.32
Drugs & Targets Welireg receives FDA approval in indication for adults with VHL September 03, 2021Vol.47 No.32
Drugs & Targets Keytruda + Lenvima combination receives FDA approval for frontline advanced RCC September 03, 2021Vol.47 No.32
Drugs & Targets FDA accepts sBLA for Keytruda as single agent for MSI-H/dMMR advanced endometrial carcinoma September 03, 2021Vol.47 No.32
